Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 1.00 |
| ▸ | RELA | Q04206 | 2/20 | 0.77 |
| ▸ | NQO2 | P16083 | 2/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.66 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365675 | 1.00 | CYP19A1 (1.00) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL17400865 | 0.93 | CYP19A1 (0.87) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL14387621 | 0.87 | CYP19A1 (0.77) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL13778224 | 0.87 | RELA (1.00) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL699632 | 0.87 | RELA (1.00) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL699631 | 0.87 | RELA (1.00) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL23158820 | 0.87 | RELA (0.84) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL700056 | 0.87 | RELA (0.84) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL700055 | 0.87 | RELA (0.84) | CYP19A1RELANQO2NFE2L2CYP1A1 | |
| SCHEMBL31317665 | 0.87 | RELA (0.84) | CYP19A1RELANQO2NFE2L2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698671-B1 | CHARGE-TRANSPORTING SUBSTANCE, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE BODY, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE BODY CARTRIDGE, AND IMAGING DEVICE | MITSUBISHI CHEM CORP (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2698671-A1 | CHARGE-TRANSPORTING SUBSTANCE, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE BODY, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE BODY CARTRIDGE, AND IMAGING DEVICE | Mitsubishi Chemical Corporation (JP) | 2014-02-19 | — | — | EP | disclosed |
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | CYP19A1 280/4885RELA 1924/4885NQO2 502/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | CYP19A1 291/4885RELA 2538/4885NQO2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.